Postdiagnostic metformin or statin use may reduce the risk for death among people with advanced prostate cancer, suggests an analysis of US Veteran Health Administration data.

Abhishek Srivastava and Neal Shore survey upcoming trials and promising new immunotherapies for advanced PCa, while highlighting some of the successes in PCa immunotherapy.

Intense androgen deprivation therapy before radical prostatectomy benefits some patients with locally advanced prostate cancer, report researchers who found that results may be better with a four-drug than a two-drug regimen.

Administration of abiraterone acetate alongside first-line androgen deprivation therapy could be the new standard of care for men with locally advanced or metastatic prostate cancer, say the authors of two independent phase III trials.

The HSD3B1 1245C variant allele could be used as a biomarker to predict treatment response in different groups of men with advanced prostate cancer, show two studies published in JAMA Oncology .

Men with advanced prostate cancer may derive a significant survival benefit from the concurrent use of statins alongside androgen-ablative therapies, suggest the Canadian authors of a systematic review and meta-analysis.

Magnetic resonance imaging-guided focal ultrasound therapy is a feasible treatment for grade group 2–3 prostate cancer, indicate phase 2b trial findings published in The Lancet Oncology .

A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.

medwireNews : The US FDA has authorized  the use of lutetium-177 vipivotide tetraxetan for previously treated patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

medwireNews: The EMA has recommended approval  of relugolix for the treatment of advanced hormone-sensitive prostate cancer.

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

Common treatments for metastatic castration-resistant prostate cancer are not associated with significant cognitive decline in older men, research suggests.

Platinum-based chemotherapy is active in patients with advanced castration-resistant prostate cancer and DNA repair gene alterations, shows a chart review.

Data from the phase 3 RADICALS-RT, RAVES, and GETUG-AFU 17 trials and the ARTISTIC meta-analysis suggest that observation with early salvage radiotherapy should be the standard of care for men undergoing radical prostatectomy for localized or locally advanced prostate cancer.